Sangamo Therapeutics Up 17%; Unveiled Updated Study Data

By Michael Dabaie

Sangamo Therapeutics Inc. (SGMO) shares rose 17% to $13.37 premarket Monday.

The company and Pfizer Inc. (PFE) Friday unveiled updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII activity levels.

The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII activity as measured using a chromogenic assay, with no reported bleeding events, and the response continues to be durable for as long as 24 weeks, the extent of follow-up. The two patients more recently treated at the 3e13 vg/kg dose level are demonstrating FVIII activity kinetics that appear consistent with the first two patients treated in this dose cohort at similar early time points, the companies said.

SB-525 showed dose-dependent increases in FVIII activity levels across all dose cohorts evaluated, the companies said.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

July 08, 2019 08:28 ET (12:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.